Method for preparing a vaccine antigen, resulting vaccine antigen and uses
US-10144917-B2 · Dec 4, 2018 · US
Antiviral compositions for the treatment of infections linked to coronaviruses
US11510896B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11510896-B2 |
| Application number | US-201716340346-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 20, 2017 |
| Priority date | Oct 21, 2016 |
| Publication date | Nov 29, 2022 |
| Grant date | Nov 29, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection of a human being or an animal comprising the administration to said human being or animal of a pharmaceutical or veterinary composition comprising, in a suitable pharmaceutical vehicle, at least one compound chosen from Apigenin and Berberine. 2. The method of claim 1 , wherein the pharmaceutical or veterinary composition comprises Apigenin. 3. The method of claim 1 , wherein the pharmaceutical or veterinary composition comprises Berberine. 4. The method of claim 2 , wherein the pharmaceutical or veterinary composition comprises one of the following combinations: Apigenin and Berberine; Apigenin and Monensin; or Apigenin, Berberine and Monensin. 5. The method of claim 1 , comprising an antiviral agent chosen from the group consisting of a protease inhibitor, a helicase inhibitor, and a MERS-CoV virus cell entry inhibitor. 6. The method of claim 1 , comprising an antiviral agent chosen from the group consisting of ribavirin and an interferon. 7. The method of claim 6 , wherein the interferon is interferon alpha-2b. 8. The method of claim 1 , wherein the pharmaceutical or veterinary composition is in a dosage form intended for administration by inhalation.
Assignees
Inventors
Classifications
for RNA viruses · CPC title
- A61K31/351Primary
not condensed with another ring · CPC title
Interferons {[IFN]} · CPC title
- A61K31/353Primary
3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11510896B2 cover?
- The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.
- Who is the assignee on this patent?
- Univ Claude Bernard Lyon, Inst Nat Sante Rech Med, Centre Nat Rech Scient, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/351. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).